Overexpression of EZH2 has been identified in thyroid cancer, especially in ATC, and its inhibition results in antitumoral effects in vitro and in vivo, reducing cell growth, migration, and invasion and improving differentiation of ATC cells (74,78). The gene discussed is EZH2; the disease is thyroid cancer.